Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 31.26M P/E - EPS this Y - Ern Qtrly Grth -
Income -9.93M Forward P/E 1.49 EPS next Y - 50D Avg Chg 1.00%
Sales 1.04M PEG - EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -34.00%
Recommedations 2.00 Quick Ratio 0.37 Shares Outstanding 174.66M 52W Low Chg 79.00%
Insider Own 22.40% ROA -67.90% Shares Float 135.32M Beta 2.48
Inst Own - ROE - Shares Shorted/Prior -/- Price 0.18
Gross Margin -66.80% Profit Margin - Avg. Volume 86,530 Target Price -
Oper. Margin -462.68% Earnings Date May 9 Volume 80,000 Change 8.48%
About INTELGENX TECHNOLOGIES CORPORAT

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

INTELGENX TECHNOLOGIES CORPORAT News
04/08/24 IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial
04/05/24 IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
03/22/24 IntelGenx Technologies Corp. (PNK:IGXT) Q4 2023 Earnings Call Transcript
03/21/24 IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
03/14/24 IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow
03/11/24 IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences
02/20/24 UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering
02/20/24 IntelGenx Launches Preferred Share Regulation A Offering
02/05/24 Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform
12/18/23 IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®
12/05/23 IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000
12/04/23 IntelGenx Announces Changes to its Board of Directors
11/28/23 IntelGenx Announces Shareholder Approval of Financing Transactions
11/14/23 IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease
11/13/23 IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting
11/10/23 IntelGenx Technologies Corp. (PNK:IGXT) Q3 2023 Earnings Call Transcript
11/09/23 IntelGenx Reports Third Quarter 2023 Financial Results
11/06/23 IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with Tilray
11/02/23 IntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 – Conference Call to Follow
09/21/23 IntelGenx Provides RIZAFILM® U.S. Commercialization Update
IGXT Chatroom

User Image Byan43 Posted - 1 day ago

$IGXT any news?

User Image AllinBallin Posted - 04/29/24

$IGXT

User Image AllinBallin Posted - 04/09/24

$IGXT

User Image DonCorleone77 Posted - 04/08/24

$IGXT IntelGenx doses first patients in Phase 2 'MONTPARK' trial IntelGenx announced that Montelukast VersaFilm has been administered to the first Parkinson's Disease patients in the Phase 2 clinical trial. MONTPARK is a Phase 2, randomized, double-blind, placebo-controlled, parallel arm, multicentre trial that will investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD. The study will enroll up to 90 patients who will receive 30 mg Montelukast VersaFilm or placebo twice daily for 18-months, followed by a 3-month washout period. Eligible candidates must be on levodopa treatment at the time of enrolment and may also be on other dopaminergic symptomatic agents. MONTPARK is being conducted at the Karolinska University Hospital and at three other Swedish University affiliated institutions under IntelGenx's previously announced research collaboration with Per Svenningsson, MD, PhD, who is serving as the study's Lead Principal Investigator.

User Image axelvento999 Posted - 04/05/24

$IGXT The CRL includes a request for additional Pharmaceutical Quality information IntelGenx Updates Status of Buprenorphine Buccal Film ANDA https://www.intelgenx.com/newsrooms/newsrooms1/134-2024-news/1010-ntelenxpdatestatusofuprenorphineuccalilm20240405

User Image WaspofWallStreet Posted - 03/27/24

$IGXT C.K.C.S. D = dbags.

User Image DonCorleone77 Posted - 03/21/24

$IGXT IntelGenx reports Q4 EPS (1c) vs (1c) last year Reports Q4 revenue $426,000 vs $173,000 last year. "We successfully executed against key strategic priorities in 2023, the most important of which was to lay the groundwork for our product pipeline and services portfolio to start generating significant revenues in 2024," commented Dwight Gorham, IntelGenx's CEO. "To that end, we expect that our commercial partner for RIZAFILM(R)1, Gensco Pharma, will be launching the product in the United States in Q2-2024, an anticipated inflection point for our business."

User Image yft212 Posted - 03/14/24

$IGXT IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full year 2023 financial results before market open on Thursday, March 21, 2024.

User Image Stockinvestor73 Posted - 03/11/24

$IGXT Shouldn't there have been an fda decission already? WTF is going on?

User Image yft212 Posted - 03/11/24

$IGXT IntelGenx Enters Into a Third Amended and Restated Loan Agreement With Atai Life Sciences

User Image illadvisedtrader Posted - 03/08/24

$IGXT https://www.stocktitan.net/news/IGXT/intel-genx-provides-regulatory-update-for-xiromed-partnered-hlk0et2bmvkf.html

User Image DoctorEmmettBrown Posted - 03/08/24

$IGXT they don’t want you to be millionaires

User Image Fordalonghaul Posted - 03/08/24

$IGXT FDA decision today!!!

User Image Carbondale45 Posted - 03/07/24

$IGXT when will this company get its ass in gear and make some profits ?

User Image AllinBallin Posted - 03/06/24

$IGXT hi

User Image AllinBallin Posted - 03/04/24

$IGXT crazy that no one is here. Maybe I’m the crazy one

User Image joesquared Posted - 2 months ago

$IGXT This news was released on 20th Feb 2024. https://www.intelgenx.com/newsrooms/newsrooms1/134-2024-news/979-ntelenxaunchesreferredhareegulation20240220

User Image Carbondale45 Posted - 02/29/24

$IGXT cure those pets.

User Image Carbondale45 Posted - 02/28/24

$IGXT Cure those pets, when does this go to market.

User Image igxtipci Posted - 02/11/24

$IGXT Anyone know whats happening with gSUB?

User Image WaspofWallStreet Posted - 02/11/24

@GoingLong2020 @TIG2 $IGXT Run by the same clueless criminals for the last 20 years

User Image BioTuesdays Posted - 02/05/24

Studies validate advantages of administering drugs to pets via IntelGenx’s VetaFilm platform $IGX $IGXT https://biotuesdays.com/2024/02/05/studies-validate-advantages-of-administering-drugs-to-pets-via-intelgenxs-vetafilm-platform/

User Image DonCorleone77 Posted - 02/05/24

$IGXT IntelGenx announces results from POC study of VetaFilm platform IntelGenx announced positive results from a proof-of-concept, POC, study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx's VetaFilm platform in healthy dogs and cats. The POC study was conducted through a research collaboration with the University Prince Edward Island, one of North America's leading veterinary universities. Key findings included: The VetaFilm FDOFs were well accepted and well tolerated by both dogs and cats; Repeated dosing showed high continued acceptance rates in both species with little or no effect of time on the continued acceptance of the VetaFilm FDOFs; Overall, 100% of dog owners and 67% of cat owners felt that administration of the VetaFilm FDOFs was "very easy" or "easy"; and 95% of dog owners and 82% of cat owners identified VetaFilm FDOFs as the preferred method of medication administration.

User Image Fordalonghaul Posted - 01/31/24

$IGXT Getting interesting! Almost 2 million shares acquired by employees today!! https://www.intelgenx.com/investors/regulatory-filings

User Image Waracken Posted - 01/29/24

$IGXT https://psychedelicvantage.com/2024/01/12/atai-life-sciences-best-kept-secret-intelgenx-igxt-video/

User Image Byan43 Posted - 01/23/24

$IGXT https://www.intelgenx.com/investors/investors-presentations Profitable 2024?

User Image Byan43 Posted - 01/19/24

$IGXT remember when this hit $1.20+. Some day we will see that again.

User Image ixchell Posted - 01/17/24

$IGXT can anyone post any real financial data about them?? Can’t find much.

User Image eloquence Posted - 01/17/24

$ATAI $CMPS $CYBN atai Life sciences' best kept secret: Intelgenx $IGXT https://youtu.be/CWW3noO0ym8?si=tjUeXBdNNo4tubhl

Analyst Ratings
HC Wainwright & Co. Buy Mar 30, 20
HC Wainwright & Co. Buy Jun 30, 14
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Zerbe Horst G Chief Executive Offi.. Chief Executive Officer Sep 30 Buy 0.13 19,000 2,470 368,064 10/03/22
Godin Andre President and CFO President and CFO Sep 29 Buy 0.124 5,000 620 308,399 10/03/22
Godin Andre President and CFO President and CFO Sep 27 Buy 0.13 10,000 1,300 303,399 09/29/22
Kenny Tommy VP IP Legal Affairs-.. VP IP Legal Affairs-Subsidiary Sep 26 Buy 0.135 19,000 2,565 138,500 09/28/22
Kenny Tommy VP IP Legal Affairs-.. VP IP Legal Affairs-Subsidiary Sep 22 Buy 0.15 33,500 5,025 119,500 09/26/22
Godin Andre President and CFO President and CFO Sep 21 Buy 0.134 20,000 2,680 293,399 09/22/22
Matzen Dana VP BD & Corp.Dev.of.. VP BD & Corp.Dev.of Subsidiary Sep 21 Buy 0.138 25,000 3,450 75,000 09/22/22